SLC8B1 and prostate cancer: Interestingly, while not directly linked to changes in NCLX expression in the tumor cells tested, the NCLX inhibitor CGP37157 was able to sensitize chemoresistant melanoma, osteosarcoma, and prostate cancer cells to pro-apoptotic tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) [135,136].